SELLAS Life Sciences Group, Inc. Share Price
Equities
SLS
US81642T2096
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.24 USD | +2.48% | -23.93% | +16.98% |
Sales 2024 * | - | Sales 2025 * | 50.61M 4.06B | Capitalization | 69.77M 5.59B |
---|---|---|---|---|---|
Net income 2024 * | -40M -3.21B | Net income 2025 * | -50M -4.01B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.38 x |
P/E ratio 2024 * |
-1.09
x | P/E ratio 2025 * |
-1.08
x | Employees | 16 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.5% |
Latest transcript on SELLAS Life Sciences Group, Inc.
1 day | +2.48% | ||
1 week | -23.93% | ||
1 month | +22.77% | ||
3 months | +93.75% | ||
6 months | +27.82% | ||
Current year | +16.98% |
Managers | Title | Age | Since |
---|---|---|---|
Angelos Stergiou
FOU | Founder | 48 | 02/04/06 |
John Burns
DFI | Director of Finance/CFO | 39 | 30/04/13 |
Andrew Elnatan
LAW | General Counsel | - | 04/01/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 28/12/17 | |
David Scheinberg
BRD | Director/Board Member | 68 | 30/11/17 |
John Varian
BRD | Director/Board Member | 64 | 28/12/17 |
Date | Price | Change | Volume |
---|---|---|---|
30/04/24 | 1.24 | +2.48% | 1,103,010 |
29/04/24 | 1.21 | -17.12% | 3,332,762 |
26/04/24 | 1.46 | -3.95% | 1,292,455 |
25/04/24 | 1.52 | -1.30% | 657,949 |
24/04/24 | 1.54 | -5.52% | 1,318,570 |
Delayed Quote Nasdaq, April 30, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.98% | 68.08M | |
-3.46% | 102B | |
+1.41% | 96.29B | |
+2.13% | 22.18B | |
-15.84% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.65% | 16.36B | |
+4.39% | 13.97B | |
+31.35% | 12.17B |
- Stock Market
- Equities
- SLS Stock